Cardioprotective effects of calcitonin gene-related peptide in isolated rat heart and in H9c2 cells via redox signaling by Tullio, Francesca et al.
Biomedicine & Pharmacotherapy 90 (2017) 194–202Original article
Cardioprotective effects of calcitonin gene-related peptide in isolated
rat heart and in H9c2 cells via redox signaling
Francesca Tullioa,1, Claudia Pennaa,*,1, Karine Cabialea,b, Saveria Femminòa,
Marco Gallonib, Pasquale Pagliaroa,*
aDepartment of Clinical and Biological Sciences, University of Turin, Italy
bDepartment of Veterinary Science, University of Torino, Italy
A R T I C L E I N F O
Article history:
Received 10 January 2017
Received in revised form 10 March 2017








A B S T R A C T
The calcitonin-gene-related-peptide (CGRP) release is coupled to the signaling of Angeli's salt in
determining vasodilator effects. However, it is unknown whether CGRP is involved in Angeli’s salt
cardioprotective effects and which are the mechanisms of protection. We aimed to determine whether
CGRP is involved in myocardial protection induced by Angeli’s salt. We also analyzed the intracellular
signaling pathway activated by CGRP. Isolated rat hearts were pre-treated with Angeli’s salt or Angeli’s
salt plus CGRP8-37, a specific CGRP-receptor antagonist, and subjected to ischemia (30-min) and
reperfusion (120-min). Moreover, we studied CGRP-induced protection during oxidative stress (H2O2)
and hypoxia/reoxygenation protocols in H9c2 cardiomyocytes. Cell vitality and mitochondrial membrane
potential (DYm, MMP) were measured using MTT and JC-1 dyes. Angeli’s salt reduced infarct size and
ameliorated post-ischemic cardiac function via a CGRP-receptor-dependent mechanism. Pre-treatment
with CGRP increased H9c2 survival upon challenging with either H2O2 (redox stress) or hypoxia/
reoxygenation (H/R stress). Under these stress conditions, reduction in MMP and cell death were partly
prevented by CGRP. These CGRP beneficial effects were blocked by CGRP8-37. During H/R stress, pre-
treatment with either CGRP-receptor, protein kinase C (PKC) or mitochondrial KATP channel antagonists,
and pre-treatment with an antioxidant (2-mercaptopropionylglycine) blocked the protection mediated
by CGRP. In conclusion, CGRP is involved in the cardioprotective effects of Angeli’s salt. In
H9c2 cardiomyocytes, CGRP elicits PKC-dependent and mitochondrial-KATP-redox-dependent mecha-
nisms. Hence, CGRP is an important factor in the redox-sensible cardioprotective effects of Angeli's salt.




Calcitonin gene-related peptide (CGRP) is a transmitter originated
by tissue-specific splicing of the calcitonin gene mRNA and it is one
of the main constituent neuropeptides of sensory nerves endings,
from which it is released following a variety of stimuli [1–3]. CGRPAbbreviations: AS, Angeli’s salt; CHE, chelerythrine; CTRL, Control; dLVP,
developed left ventricular pressure; dP/dtmax, first derivative of ventricular
pressure during systole; H/R, hypoxia/reoxygenation; LDH, lactate dehydrogenase;
LVEDP, left ventricular end diastolic pressure; LVP, left ventricular pressure; mKATP,
mitochondrial KATP channels; mKATP, mitochondrial KATP channels; MPG, 2-
mercaptopropionylglycine; MMP, mitochondrial membrane potential; 5-HD, 5-
hydroxydecanoate.
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0753-3322/© 2017 Elsevier Masson SAS. All rights reserved.is also present in the heart, where it induces vasodilatation and
exerts positive inotropic and chronotropic effects [1,2,4,5].
Ischemic pre- and post-conditioning (i.e. short periods of
ischemia applied immediately before or after ischemia) provide
protection against ischemia/reperfusion (I/R) injury. Studies have
involved CGRP in both pre- and post-conditioning cardioprotection
[6,7]. Various studies report that the reduction I/R injury in
response to ischemic conditioning or cardioprotective agents, such
as adenosine, bradykinin and opioids, takes place via nitric oxide
(NO)-dependent pathway [8,9].
In vivo studies have shown that CGRP release may be induced by
the nitroxyl (HNO) donor Angeli's salt (AS). In normal and failing
hearts, while the intravenous AS infusion increased circulating
levels of CGRP, the blockade of CGRP-receptor, by the specific
antagonist (CGRP8-37), prevented AS inotropic/lusitropic action
[10–12].
Besides HNO, AS may also release nitrite. It is well known that
NO, nitrite and nitrate donors can induce preconditioning-like
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sition of AS, can induce redox-sensible myocardial protection
against reperfusion injury, which is blocked by N-acetyl-cysteine
[17]; this thiol-donating agent can discriminate the effect of HNO
from that of other nitrogen derived molecules. Indeed, AS/HNO
action can be blocked by this agent, whereas the NO effect is
potentiated [12].
Importantly, in rat coronary vasculature, AS is a potent
vasodilator agent via CGRP release and potassium ATP channel
activation [18–21]. Also nitroglycerin (NTG), a NO/nitrate donor,
may exert protection against reperfusion injury via CGRP and
protein kinase C (PKC) signaling [9,15,22]. Indeed, while NTG
infusion increased CGRP release in coronary effluent, NTG-induced
cardioprotection was blocked by CGRP8-37 [22]. Therefore, there is
an evident cross-talk between CGRP and nitrogen derived
compounds, including HNO [18–22]. Whatever the mechanism,
many stimuli, including HNO, induce the release of CGRP. In
particular, it has been proposed that HNO activates the sensory
chemoreceptor channel and as a consequence CGRP is released,
mediating local and systemic vasodilation [5].
Although it has been suggested that AS may induce the release
of CGRP [11,19–21] and it has been suggested that exogenous and
endogenous CGRP may have cardioprotective effects (both pre-
and post-conditioning like effects) [1,4,22,23–26], no study has
linked CGRP to AS-induced preconditioning.
When CGRP has been infused before ischemia it resulted
protective [4,27–30], even in the presence of comorbidities, such as
diabetes and hypertension [4,27]. Moreover, the infusion of CGRP
after ischemia induced postconditioning-like cardioprotection
[25].
Since cardioprotection, induced by either ischemic pre- or post-
conditioning, is mediated by the activation of PKC and mitochon-
drial KATP (mKATP) channels, leading to a reactive oxygen species
(ROS) signaling [9,31,32], we hypothesized a similar intracellular
signaling pathway for CGRP-induced myocardial protection.
Therefore, here we sought to determine whether CGRP-CGRP-
receptor interaction is involved in myocardial protection. More-
over, we aimed to dissect the protective intracellular signaling
activated by CGRP.
To this aim, we first ascertained the possibility to induce
cardioprotection via CGRP-receptor activation in isolated rat hearts
subjected to ischemia/reperfusion. In this experimental model AS
was used as a tool to induce endogenous CGRP-CGRP-receptor
interaction. Then, to test the hypothesis that CGRP protects against
the myocardium injury via the activation of CGRP-receptor, PKC
and mKATP/ROS signaling, we used as model the rat cardiomyocyte
cell line H9c2. In these cells we studied the ability of CGRP to
protect against oxidative stress and hypoxia/reoxygenation in the
absence and in the presence of the specific inhibitors of
aforementioned signaling molecules and CGRP-receptor antago-
nist.
2. Materials and methods
2.1. Animals
Male Wistar rats were used in compliance with the European
Council directives (No. 86/609/EEC) and with Italian law (DL-116,
January 27, 1992). They are in agreement with the Guide for the
Care and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised 1996) and
follow the U.K. Animals (Scientific Procedures) Act, 1986 and
associated guidelines.2.2. Study of the role of CGRP on cardioprotective effects of Angeli's salt
in an ex-vivo model
The methods were similar to those previously described
[17,33,34]. In brief, isolated hearts were weighed, attached to
the perfusion apparatus and retrograde perfused with oxygenated
Krebs–Henseleit buffer (pH 7.34), containing (in mM): 127 NaCl,
17.7 NaHCO3, 5.1 KCl, 1.5 CaCl2, 1.26 MgCl2, 11 D-glucose and gassed
with 95% O2 and 5% CO2. A constant flow was adjusted with a
proper pump to obtain a typical coronary perfusion pressure of 80–
85 mmHg during the initial part of stabilization. Thereafter the
same flow level (9  1 mL/ min/g) was maintained throughout the
experiment. A small hole in the left ventricular wall allowed
drainage of the thebesian flow, and a polyvinyl-chloride balloon
was placed into the left ventricle and connected to an electro-
manometer for the recording of left ventricular pressure (LVP)
during isovolumetric contraction. The balloon was filled with
saline to achieve an end-diastolic LVP of 5 mmHg in baseline
conditions. Coronary perfusion pressure, coronary flow and LVP
were monitored to assess the preparation conditions. LVP was used
to calculate the positive first derivative of pressure during systole
(dP/dtmax). Developed LVP (dLVP) was obtained subtracting left
ventricular end diastolic pressure (LVEDP) from peak systolic LVP.
Data were analyzed in pre- and post-ischemic phase during at least
15-s of stable conditions (i.e. in the absence of arrhythmias).
The hearts were electrically paced at 280 bpm and kept in a
temperature-controlled chamber (37 C).
2.2.1. Experimental protocols for isolated hearts (Fig. 1, panel A)
Each heart was allowed to stabilize for 30-min. After the
stabilization period, hearts were subjected to a specific protocol,
which included in all groups a 30-min of global no-flow ischemia. A
period of 120-min reperfusion followed the 30-min ischemia in all
groups (see below). Pacing was discontinued on initiation of
ischemia and restarted after the third minute of reperfusion in all
groups.
Hearts in the control group (I/R Group, n = 7) were perfused
with buffer only for an additional 29-min after stabilization (see
Fig. 1A) before to be subjected to I/R protocol.
In Angeli’s salt Group (n = 7), hearts were exposed to AS (1 mM)
for 19-min followed by a 10-min buffer wash-out (WO) period
[17,35]. In a group, (CGRP8-37, n = 3) the effect of I/R was examined
in hearts pre-exposed to only CGRP8-37 (0.1 mM), the CGRP receptor
antagonist, for a total of 29-min. In another group, (AS + CGRP8-37,
n = 7) the role of CGRP in AS-induced protection was examined in
hearts where AS (1 mM) effects were evaluated during the co-
infusion with CGRP8-37 (0.1 mM). Also in this case the antagonist
(CGRP8-37, 0.1 mM) was infused for a total of 29-min, starting 5-min
prior to AS administration and continued up to 5-min from the
discontinuation of the 19-min AS infusion [28,29].
2.2.2. Assessment of myocardial injury
2.2.2.1. LDH assay. In isolated rat heart, preconditioning has been
observed to lead to a 50% reduction in lactate dehydrogenase (LDH)
release following 30-min ischemia. Consistently, samples of
coronary effluent (2 mL) were withdrawn with a catheter
inserted into the right ventricle via the pulmonary artery.
Samples were extracted immediately before ischemia and at 3,
6, 10, 20 and 30 min of reperfusion and thereafter every 20 min.
LDH release was measured as previously described [17,36]. Data
are expressed as cumulative values for the entire reflow period.
Fig. 1. Timeline of the three experimental protocols.
A: Protocols of ischemia/reperfusion (I/R) in isolated rat hearts. Angeli’s salt (AS) was given for 19 min and CGRP8-37 was given for 29 min starting 5 min before AS and was
continued 5 min after AS infusion was stopped. WO: wash out.
B: Protocols of oxidative stress (H2O2) in H9c2 cells.
C: Protocols of hypoxia/reoxygenation (H/R) in H9c2 cells (Normoxic subgroups are not represented).
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye is used as colorimetric assay for assessing cell metabolic activity, reflecting the number of viable
cells present.
JC-1: 5,50 ,6,60-tetraethylbenzimidazolylcarbocyanine iodide, a cationic carbocyanine dye that accumulates in mitochondria. It is a sensitive marker for mitochondrial
membrane potential. For further explanations and other abbreviations see the text.
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after reperfusion, each heart was rapidly removed from the
perfusion apparatus, and the left ventricle (LV) was dissected into
2–3 mm circumferential slices. Following 15-min of incubation at
37 C in 0.1% solution of nitro-blue tetrazolium in phosphate buffer
(pH 7.2) unstained necrotic tissue was carefully separated from
stained viable tissue by an independent observer who was not
aware of the nature of the intervention. The weights of the necrotic
and non-necrotic tissues were then determined, and the necroticmass was expressed as a percentage of total left ventricular mass
[17,35].
2.3. Study of protection against oxidative stress and study of
intracellular mechanisms of CGRP protection against hypoxia/re-
oxygenation in an in vitro model: H9c2 cells (Fig. 1 panels B and C)
We aimed to assess the effects of alpha-CGRP (hereafter CGRP)
in H9c2, a cardiac cell line that responds to different stimuli with
Table 1
Hemodynamic parameters before ischemia and at the end of reperfusion.
Group Before ischemia At the end of reperfusion
dLVP dP/dtmax LVEDP dLVP dP/dtmax LVEDP
I/R 85  4 2640  106 5  1 23  4*** 969  74*** 49  2**
AS 83  5 2947  161 4  1 43  5*,# 1540  79*,# 18  4*,#
CGRP8–37 87  3 2779  56 6  1 30  5* 935  76* 48  17**
AS + CGRP8–37 89  4 2827  196 6  2 39  4* 1255  78* 45  19**
dLVP: developed left ventricular pressure; dP/dtmax: maximum rate of increase of
LVP during systole; LVEDP: left ventricular end diastolic pressure.
* p < 0.05.
** p < 0.01.
*** p < 0.001 vs basal condition.
# p < 0.05 vs I/R.
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Commercially available H9c2 were obtained from American Type
Culture Collection (ATCC; Manassas, VA). H9c2 were grown in
Dulbecco’s Modified Eagle’s Medium Nutrient mixture F-12 HAM
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1%
(v/v) streptomycin/penicillin (Wisent Inc, Quebec, Canada) at
37 C, 5% CO2 [37].
In all sets of experiments when cells reached 80% confluence
were removed from the flask, counted in the Burker chamber and
plated in 96 wells plate with 5000 cells/well density. Cells were
then left for 24-h in standard colture conditions, before to be
subjected to H2O2 or hypoxia/reoxygenation (H/R) protocols.
2.3.1. H2O2 Protocols (Fig. 1 panel B)
Cells were treated only with DMEM for a total of 7-h (CTRL
group). Cells, after 3-h DMEM, were exposed to H2O2 (50 mM) for
2-h and then to WO with DMEM for other 3-h (H2O2 group). Groups
of cells were pre-treated for 3-h with CGRP (0.1 mM, CGRP group)
or CGRP8-37 (0.1 mM, CGRP8-37 group) or CGRP plus CGRP8-37,
dissolved in DMEM-2% FBS. Then, in pre-treated subgroups, H2O2
(50 mM) was given for 2-h, instead of DMEM (untreated groups)
[38]. At the end of H2O2 stress, the medium was changed with fresh
DMEM (3-h WO). Finally, a MTT assay and an evaluation of the
mitochondrial membrane potential (MMP) were performed (see
infra, “Cell survival assessment” and “Measurement of mitochondrial
membrane potential (JC-1)”).
2.3.2. Hypoxia/Reoxygenation (H/R) protocols (Fig. 1 panel C)
In this set of experiments for comparative purpose groups of
cells were left in normoxic conditions (not represented in figure).
As Normoxia (N) we considered cell survival studied during
standard H9c2 culture conditions (21% O2 and 5% CO2).
As Hypoxia/Reoxygenation (H/R) we considered cell survival
studied after exposition to DMEM-2% FBS with 3% O2 and 5% CO2
for 72-h and a subsequent reoxygenation (21% O2 and 5% CO2) for
3-h [39–42]. H/R protocol was obtained in an hypoxic chamber
(INVIVO2 200, Belsar, Varese, Italy).
During 24-h standard colture, cells were pre-treated with CGRP
(0.1 mM) [42], or CGRP + antagonists (see below) dissolved in
DMEM-2% FBS. After the 24-h pre-treatment, subgroups remained
in normoxia (indicated by the suffix N in the following
description and not represented in Fig. 1C), whereas other cells
underwent H/R (indicated by the suffix H/R and represented in
Fig. 1C).
Therefore, the experimental groups were:
a.) Control Groups, untreated cells: CTRL-N; CTRL-H/R.
b.) CGRP Groups, cells pre-treated with CGRP only (0.1 mM): CGRP-
N; CGRP-H/R.
c.) CGRP + antagonists, cells pre-treated with CGRP plus antago-
nist, in particular:
 CGRP + CGRP8-37 (0.1 mM, [42]): CGRP + CGRP8-37-N; CGRP +
CGRP8-37-H/R.
 CGRP + inhibitor of PKC (chelerythrine, CHE; 5 mM [4]): CGRP +
CHE-N; CGRPa+CHE-H/R.
 CGRP + mKATP-channel inhibitor (5-hydroxydecanoate, 5-HD,
300 mM [40]): CGRP + 5-HD-N; CGRP + 5-HD-H/R.
 CGRP + antioxidant (2-mercaptopropionylglycine, MPG, 100 mM
[15]): CGRP + MPG-N; CGRP + MPG-H/R.
Moreover, all antagonists were tested alone in normoxia and H/
R conditions (each group has 2 subgroups, i.e., N and H/R, not
represented in Fig. 1C).2.3.3. Cell survival assessment
At the end of experiments cell survival was assessed using the
cell viability test 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) kit. The plates were read by a spectropho-
tomer at 570 nm to obtain values of optical density [39]. All values
were normalized to mean value of input control cells and
expressed as percentage.
2.3.4. Measurement of mitochondrial membrane potential (JC-1)
The MMP was evaluated with the fluorescent dye JC-1 (5,50,6,60-
tetraethylbenzimidazolylcarbocyanine iodide; Molecular Probes,
Eugene, OR, USA). In brief, sub-groups of cells were incubated with
JC-1-containing medium (10 mg/ml) at 37 C for 20 min, washed
two times with PBS and analyzed using a fluorescence microplate
reader. The ratio between red and green JC-1 florescence was
considered a quantitative index of mitochondrial membrane
potential [43]. All values were normalized to mean value of
control group and expressed as percentage.
2.4. Chemicals
The HNO donor Angeli’s salt (sodium trioxodinitrate, Na2N2O3)
was a generous gift of Dr. Jon M. Fukuto (University of California,
Los Angeles, CA). If not differently specified, chemicals and kits
have been purchased from Sigma-Aldrich, St. Louis, MO, USA. Stock
solutions of Angeli’s salt (100 mM in 10-mM NaOH) and of other
compounds were diluted in buffer immediately prior to use, as
previously described [17,44].
2.5. Statistical analysis
All values are presented as means  SEM. All data were
subjected to t-test, ANOVA and Tukey's Multiple comparison




In isolated rat heart, Angeli’s salt (AS, 1 mM) reduced infarct size
and ameliorated post-ischemic myocardial function. Baseline
functional parameters and post-ischemic myocardial function
are summarized in Table 1.
3.1.1. Angeli’s salt is a cardioprotective agent when it is infused before
ischemia/reperfusion
Consistently with previously reported data [17], as shown in
Fig. 2A, pre-treatment with AS (1 mM) resulted in a significant
reduction of infarct size (37.9  3.5% of left ventricle, LV) with
respect to I/R group (66.6  6.4% of LV, p < 0.001). Infarct size data
Fig. 2. Infarct size and LDH release.
A: Infarct size. Infarct area expressed as percentage of the left ventricle (LV) mass
resulted smaller in Angeli's salt (AS) Group compared with ischemia/reperfusion (I/
R), CGRP8-37 and AS + CGRP8-37 Groups.
B: LDH release. The increase in LDH concentrations during reperfusion was lower in
AS Group than in I/R, CGRP8-37 and AS + CGRP8-37 Groups.
** p < 0.01 and *** p < 0.001 vs I/R. # p < 0.05 vs AS.
Fig. 3. Left ventricle contractile function impairment.
A: Developed LVP (dLVP). dLVP expressed as percentage fall resulted smaller in
Angeli's salt (AS) Group respect to ischemia/reperfusion (I/R), CGRP8-37 and
AS + CGRP8-37 Groups.
B: first derivative of pressure during systole (dP/dtmax). dP/dtmax expressed as
percentage recovery resulted lower in AS Group respect to I/R, CGRP8-37 and
AS + CGRP8-37 Groups.
*** p < 0.001 vs I/R. # p < 0.05 vs AS.
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was about 1600 U/mg and it was significantly reduced by AS to
about 900 U/mg (p < 0.01 vs I/R).
3.1.2. CGRP receptor blockade prevents Angeli’s salt-induced reduction
of myocardial injury
The selective receptor blocker CGRP8-37 (0.1 mM) did not alter
basal coronary resistance, cardiac performance (Table 1), and I/R
injury (Fig. 2). The co-infusion of CGRP8-37 with AS prevented
myocardial protection afforded by AS alone. The infarct size
(63.6  7.9%, Fig. 2A) was not different from the value found in I/R
and CGRP8-37 groups (p = NS, AS + CGRP8-37 vs I/R and vs CGRP8-37),
but significantly different from that reported in AS treated hearts
(p < 0.05, AS + CGRP8-37 vs AS, Fig. 2A). Consistently, LDH release in
control I/R group was superimposable to the release observed in
CGRP8-37 and AS + CGRP8-37 groups (p = NS vs I/R for both groups),
but significantly higher from AS alone (p < 0.05, AS + CGRP8-37 vs
AS, Fig. 2B).
3.1.3. Recovery of post-ischemic left ventricle contractile function is
improved by Angeli’s salt via a CGRP mechanism
In post-ischemic phase left ventricle contractile function was
impaired in all groups (Table 1, row data and Fig. 3 percent
variations). In control I/R group dLVP dropped from 85  4 mmHg
during pre-ischemia to 23  4 mmHg at end of reperfusion
(67  3%, p < 0.001 vs pre-ischemia values; Fig. 3A). However,
this negative trend was significantly ameliorated by AS pre-
treatment (dLVP dropped by 42  5% only; p < 0.001 vs control
group; Fig. 3A). Similarly, in control I/R group the rate of change ofleft ventricular pressure (peak of dP/dtmax) was reduced by about
60% (p < 0.001 vs pre-ischemia, Fig. 3B) and by about 45% only in
AS pretreated hearts (p < 0.05 vs controls; Fig. 3B). Although
CGRP8-37 given alone in pre-ischemic phase did not avoid the
reduction of dLVP and dP/dtmax induced by I/R, when co-infused
with AS it prevented the beneficial effects of AS on both dLVP and
dP/dtmax recovery (Table 1 and Fig. 3A and B).
As can be seen in Table 1, in control I/R group LVEDP increased
from about 5 mmHg during pre-ischemia to about 50 mmHg at end
of reperfusion (p < 0.01 vs pre-ischemia values). However, this
dramatic increase was significantly blunted by AS pre-treatment
(LVEDP increased from about 4 mmHg to about 18 mmHg only;
p < 0.05 vs control group, Table 1). The improvement on LVEDP
increase induced by AS was prevented by the addition of CGRP8-37,
which per se did not affect I/R-induced LVEDP elevation. Yet, the
post-ischemic levels of coronary perfusion pressure were not
affected by AS, CGRP and/or CGRP8-37 pre-treatment (data not
shown).
These results suggest that AS may trigger the endogenous
release of CGRP, which may act on their own receptors to mediate
cardioprotection.
3.2. In-vitro models
3.2.1. Cell death by H2O2 was limited by CGRP pre-treatment
In Fig. 4 cell count is reported as percent value with respect to
the mean value in the control group: the oxidative stress by H2O2
Fig. 4. Cell vitality and mitochondrial membrane potential in H9c2 subjected to H2O2 treatment.
A: Effects of CGRP and its specific antagonist (CGRP8-37) on cellular mortality induced by oxidative stress with H2O2. Data are normalized to mean value of cell count in control
conditions and expressed as percentage.
B: Measurement of mitochondrial membrane potential with JC-1 in H9c2 in the presence and in the absence of H2O2 with and without CGRP and its specific antagonist
(CGRP8-37). Data are normalized to mean value in control conditions and expressed as percentage.
*** p < 0.001 vs Control. # p < 0.05 and ## p < 0.01 vs CGRP + H2O2.
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87  2%; p < 0.001, CTRL vs H2O2). The pre-treatment with CGRP
ameliorated the cell survival (94  3%) in the presence of this
oxidative stress (p = NS, CGRP+ H2O2 vs CTRL group). However, the
co-presence of CGRP8-37 abolished the protective effect induced by
CGRP (cell survival 84%  2; p < 0.01 CGRP + H2O2 vs CGRP + CGRP8–
37 + H2O2). No differences are observed with respect to the CTRL
group when CGRP or CGRP8-37 were given alone (cell survival
101 4% and 97  2%, respectively). Moreover, as can be seen in
Fig. 4B, oxidative stress by H2O2 led to a reduction of JC-1 red/green
ratio, which is representative of a marked reduction of MMP.
Importantly, CGRP pre-treatment prevented the MMP reduction
caused by oxidative stress and the co-presence of CGRP8-37
abolished the protective effect induced by CGRP pre-treatment.
3.2.2. CGRP per se has no effect on cell proliferation in normoxic
conditions, but improves cell survival after H/R
In Fig. 5A, the effects of normoxia and H/R in untreated cells
(Control) and after CGRP-pretreatment are reported. Data are
presented as percent variation (mean  SEM) with respect to mean
value of cell count in normoxia. The analysis of viability in
normoxia showed that 24-h pre-treatment with CGRP did not
influence cell number: we found that there were no significant
differences in cell viability between untreated cells and CGRP
treated cells (CTRL-N 100  2% vs CGRP-N = 104  4%, p = NS). In the
absence of pre-treatment, the H/R protocol induced a significant
reduction of cell vitality with respect to CTRL-N (CTRL-N 100  2%
vs CTRL-H/R 87  2%, p < 0.01). The pre-treatment with CGRP
protected the cells and reduced significantly the mortality by H/R
(Control-N 100  2% vs CGRP-H/R = 98  2%, p = NS).
3.2.3. Cell survival after H/R was improved by CGRP pretreatment via
PKC/mKATP/ROS signaling
In Fig. 5B the effects of H/R in CGRP treated cells and after
CGRP + antagonists pre-treatment are reported. Either CGRP8-37,
the CGRP receptor antagonist, or CHE, the inhibitor of PKC, or 5-HD,
the mKATP channels blocker, abolished the protective effect
induced by CGRP pre-treatment against H/R (p < 0.05 for all vsCGRP-N). Also, the treatment with the anti-oxidant MPG abolished
the protective effect of CGRP in hypoxic condition (CGRP-N vs
CGRP + MPG-H/R, p < 0.01). Importantly, the cell vitality in all H/R
groups pre-treated with CGRP + antagonists was significantly
lower than cell vitality in CGRP-H/R group. These results suggest
that CGRP is an important protective factor during hypoxia able to
trigger the PKC/mKATP/ROS signaling.
Finally, the antagonists alone did not avoid H/R detrimental
effects, with the exception of the antioxidant, MPG. In this group, in
fact, there was not a reduction of cell vitality after H/R (Fig. 5C).
To corroborate MTT data, we ascertained the effect of H/R on
MMP. As can be seen in Fig. 5D, H/R protocol led to a reduction of
JC-1 red/green ratio, i.e. H/R reduced MMP. CGRP pre-treatment
prevented the MMP reduction caused by H/R.
4. Discussion
Here we demonstrate, for the first time, that the endogenous
neuropeptide CGRP and receptor are involved in the protective
effects induced by pre-treatment with AS, in cardiac ex vivo model.
We also demonstrate that CGRP protects either against oxidative
stress or hypoxia/reoxygenation the H9c2 cells. In this cellular
model protection against H/R may occur via a PKC and mKATP/ROS-
dependent signaling pathway, preserving MMP. Our results are in
line with the recent observation that CGRP improves hypoxia-
induced inflammation and apoptosis via NO in H9c2 [45].
In the isolated heart the infusion of AS, in a preconditioning like
manner, reduces the infarct size and improves post-ischemic
cardiac function [17]. Here we provide evidences that AS
cardioprotective effects are abolished by co-infusion of a CGRP
receptor antagonist, namely the CGRP8-37 fragment. These results
suggest that AS-protection is dependent on endogenous CGRP and
that its cardioprotective role is mediated by CGRP receptor
activation.
The H9c2 cell line was used as a bioassay to study the
intracellular mechanisms activated by CGRP–CGRP receptor
interaction to be protective. This cell line responds to CGRP with
the activation of pathways similar to adult cardiomyocytes [37,45].
Fig. 5. Survival analysis in Normoxia (N), and cell vitality and mitochondrial membrane potential in H9c2 subjected to Hypoxia/Reoxygenation (H/R) conditions.
A: treatment with CGRP in N and H/R conditions compared with control groups (N or H/R without CGRP). ** p < 0.01 vs Control-N.
B: treatment with CGRP in the presence of specific inhibitors (CGRP8-37, CHE and 5-HD) and anti-oxidant (MPG) in H/R conditions. *<p 0.05 and ** p < 0.01 vs CGRP-N; #
p < 0.05 vs CGRP-HR.
C: control of inhibitors alone in H/R conditions. * p < 0.05 ** and p < 0.01 vs Control-N.
D: measurement of mitochondrial membrane potential with JC-1 in H9c2 exposed to CGRP in N and H/R conditions and compared with control groups (N or H/R without
CGRP). *<p 0.05 vs CGRP-N; # p < 0.05 vs CGRP-HR.
Data are normalized to mean value in normoxic conditions and expressed as percentage. For acronyms see the text.
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against oxidative stress induced by H2O2. We confirmed that CGRP
is protective also against a hypoxia/reoxygenation protocol that
may “mimic” I/R conditions. While CGRP protects against hypoxia/
reoxygenation insult, it has minimal, if any, effects on
H9c2 proliferation in normoxic conditions.
In this in vitro setting we studied the intracellular pathway
involved in CGRP induced protection using a) CHE, the large
spectrum antagonist of PKC [4], b) 5-HD, the blocker of mKATP
channels [40] and c) MPG, a highly effective antioxidant with
mitochondrial affinity [8,9].
The application of either CHE or 5-HD abolishes the protective
effect of CGRP in hypoxia/reoxygenation conditions. These results
demonstrate indirectly that CGRP induces protection via activation
of PKC and opening of mKATP dependent channels. It has been
reported that the opening of these channels leads to a protective
mitochondrial ROS-signaling [9,31,32]. Indeed, the protection
induced by CGRP is likely dependent on ROS release [10]. Our
results show that the co-treatment with an anti-oxidant (MPG +
CGRP) also abolishes the protective effect against hypoxia/
reoxygenation. Yet, ROS are double-edged swords, in fact MPG
alone avoids damage by H/R. MPG seems to be specific formitochondrial ROS [8,9] and this may explain the MPG limiting
effect in CGRP-induced protection: it is likely that mitochondrial
ROS are the primary species involved in both cardiac protection
and injury [9,31,32]. We did not measure ROS generation due to the
difficulty to measure transient production and to interpret the
results obtained [46]. This is a limitation of our study to be kept in
account. Nevertheless, ROS production during hypoxia/reoxygen-
ation generally occurs in the mitochondrial electron transport
chain [47–50]. In cardioprotective context, this ROS formation may
depend on mKATP channel opening, and involve phosphorylation
and mitochondrial translocation of PKC with subsequent genera-
tion of ROS with signaling role [32,47]. Importantly, in myocytes,
the scavenging of ROS with MPG blunts the beneficial effect of
cardioprotective interventions [47,49–51].
In our experiments, the JC-1 fluorescence ratio supports the
involvement of mitochondria and MMP maintenance in the effects
mediated by CGRP, both against redox stress an H/R challenging.
Mitochondria are point of convergence for cardioprotective
signaling pathways and the alteration of mitochondrial integrity
is associated with disruption of the MMP leading to an increased
permeabilization of the mitochondrial membrane and to the
dangerous ROS-induced ROS release phenomena [31,32,43].
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together PKC activation have been proposed as important steps
of protection [48,52–55], and using inhibitors of PKC and tyrosine
kinase the nexus between ROS, kinase activity and cardioprotec-
tion has been demonstrated [53,56].
All the findings of the present study support that CGRP
protective pathways converge on mitochondria to maintain the
MMP following oxidative stress.
Nitrogen oxidative species are important components of many
physiological processes and have the potential to be useful
pharmacological agents in cardiovascular diseases. Angeli's salt
is a potent vasodilator agent acting by soluble guanylyl cyclase
dependent CGRP release and by KATP channels activation [57].
Angeli’s salt via NO and/or CGRP release may relax the coronary
vessels [18–21], an effect also observed in our model during heart
pre-treatment, as revealed by a transient drop in coronary
perfusion pressure, which quickly recovered during the wash-
out period in the pre-ischemic phase. In pilot experiments (n = 3)
we also confirmed that CGRP8-37 abolishes ischemic precondition-
ing’s cardioprotection (data not shown). Involvement of CGRP
receptors in ischemic preconditioning's cardioprotection has been
observed several times (e.g. [4,27–30]). The results of present study
suggest CGRP as redox-dependent mediator of cardioprotection.
However, we should keep in mind that AS decomposition
generates both HNO and nitrite [58] and that the release of nitrite
may have per se a cardioprotective effect [59].
With no doubt HNO donors induces CGRP release from sensory
nerve endings or from non-noradrenergic, non-cholinergic (NANC)
neurons [5,10–12,18–21]. Paolocci et al. [44] observed an increase
in circulating CGRP levels during AS treatment, which increases the
contractility of the heart (positive inotropy) [44]. However, the
same authors demonstrated that, under heart failure conditions,
CGRP does not play a major role in the HNO induced contractility,
suggesting another molecular target [10–12,19,20]. A role for AS in
the therapy of heart failure with complex redox mechanisms has
been reported [60,61]. The authors, suggested that HNO targets
thiol groups on selective proteins involved in calcium handling,
and this mechanism is probably influenced by ROS signaling.
Similar effect on redox-dependent modifications of SH group of
proteins involved in calcium handling have been reported by
several groups studying contractility and/or cardioprotection (for
reviews see [31,62]). This redox dependency of AS/CGRP effects is
in line with our present study.
4.1. Conclusions
Three key observations regarding the neuropeptide CGRP were
made in this study: (1) in whole heart, CGRP receptor activation is
involved in the cardioprotective effects of AS, an HNO donor able to
induce CGRP release [5,10,11]; (2) CGRP protects cardiac cells from
redox stress and hypoxia/reoxygenation-induced injury; and (3)
CGRP protective effects may depend upon the activation of the
CGRP receptors and the downstream PKC and mKATP/ROS
signaling, with a preservation of MMP.
If confirmed in appropriate pre-clinical model, HNO and CGRP
cardioprotective effects may be interesting mechanism to be
further investigated for a therapeutic approaches in heart failure
and cardiac ischemia/reperfusion scenarios [11].
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